Neomycin

CHEMBL3989751 Phase 4 Approuvé Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
614.6 g/mol
LogP
-9.0
Phase
4

This aminoglycoside antibiotic is used topically on the skin to prevent infection in minor cuts, burns, and wounds, and can also be taken orally to reduce bacteria in the intestines before surgery. It works by stopping bacteria from making the proteins they need to survive.

Masse moléculaire

614,6000 g/mol

LogP

-9,00

TPSA

353,00 Ų

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Mécanisme d'action

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

SMILES

C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N

InChI

InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1

Molecular Formula

C23H46N6O13

HBD / HBA

13 / 19

Liaisons Rotatives

9

Atomes Lourds

42

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This aminoglycoside antibiotic is used topically on the skin to prevent infection in minor cuts, burns, and wounds, and can also be taken orally to reduce bacteria in the intestines before surgery. It works by stopping bacteria from making the proteins they need to survive.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Neomycin is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989751. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 8378. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.